GLP-1 receptor agonists show anti-cancer benefits beyond weight loss

New research being presented at the European Congress on Obesity (ECO25) in Malaga, Spain (11–14 May) and published in the journal eClinicalMedicine finds that first-generation weight-loss medications like liraglutide and exenatide appear to show anti-cancer benefits beyond weight loss.

This article was originally published on MedicalXpress.com

You may also be interested in:

Read More:

Lawyers Lookup